Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Taps Aurora Co-founder Harry Stylli as New CEO

NEW YORK, June 1 (GenomeWeb News) - Sequenom has named Harry Stylli CEO and president, the company said today.

 

He comes to the San Diego-based firm from protein therapeutics firm Xencor of Monrovia, Calif., where he was president and CEO, and where he will remain a director. Sequenom has been without a full-time chief since February, when Toni Schuh resigned. Stylli takes over from Steve Zaniboni, who led Sequenom on an interim basis.

 

Prior to Xencor, he was president, CEO, and a co-founder of therapeutic antibody maker CovX Pharmaceuticals.

 

Stylli also co-founded Aurora Biosciences in 1995, where he was senior vice president of screening technology and new ventures, and later senior vice president of commercial development. In 2001, when Aurorawas acquired by Vertex Pharmaceuticals, he became president of Aurora and Panvera, another subsidiary of Vertex.

 

As part of his employment package at Sequenom, Stylli received stock options for 1 million shares of common stock.

 

Stylli holds a PhD from LondonUniversity's faculty of medicine, an MBA from the Open University in the UK, and a bachelor's of science degree from the Universityof East London.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.